In this regard, somatic EGFR mutations as well as gene amplification in patients with non-small cell lung cancer (NSCLC) highly correlate with the clinical response to tyrosine kinase inhibitors [14,15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.